Similar articles

• The pharmacology of selective inhibition of COX-2.

  Grosser T. Grosser T. Thromb Haemost. 2006 Oct;96(4):393-400. Thromb Haemost. 2006. PMID: 17003913 Review.
• A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials.

  Hellstrom HR. Hellstrom HR. Med Hypotheses. 2007;69(1):83-9. doi: 10.1016/j.mehy.2006.11.027. Epub 2007 Jan 12. Med Hypotheses. 2007. PMID: 17222987
• Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.

  Weber AA, Hohlfeld T, Harder S. Weber AA, et al. Thromb Haemost. 2006 Oct;96(4):413-6. Thromb Haemost. 2006. PMID: 17003916 Review.
• COX-2 inhibitors and cardiovascular risk.

  Funk CD, FitzGerald GA. Funk CD, et al. J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9. doi: 10.1097/FJC.0b013e318157f72d. J Cardiovasc Pharmacol. 2007. PMID: 18030055 Review.
• Physiology. COX-2 inhibitors and cardiovascular risk.

  Cannon CP, Cannon PJ. Cannon CP, et al. Science. 2012 Jun 15;336(6087):1386-7. doi: 10.1126/science.1224398. Science. 2012. PMID: 22700906 No abstract available.